in vivo News and Research

RSS

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, the world's most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

Clinical study: Celecoxib drug may treat breast cancer

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

5 May 2011

MiMedx introduces AmnioFix Nerve Wrap for use in surgical procedures

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix Nerve Wrap, the Company's latest biologic implant processed to offer surgical and healing options for nerve repair.

5 May 2011

Techne acquires Tocris Holdings

Techne Corporation announced today that it has acquired 100% ownership of Tocris Holdings Limited and subsidiaries, a leading supplier of reagents for non-clinical life science research.

3 May 2011

Caliper first quarter revenue increases 25% to $35.8 million

Caliper Life Sciences, Inc., today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010.

2 May 2011

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

2 May 2011

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Association's prestigious Apple Award.

30 Apr 2011

Gene therapy approach using CD59 shows promise against AMD: Study

A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration, according to a new in vivo study by researchers at Tufts University School of Medicine.

30 Apr 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

Rxi secures SBIR grants to develop novel RNAi therapeutics for ALS

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that it was awarded two Small Business Innovation Research grants from the National Institutes of Health.

27 Apr 2011

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra’s drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (“NT Life”), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

25 Apr 2011

Nano Terra, Kadmon sign deal to license novel product candidates

25 Apr 2011

Research solves challenging problem of industry-scale production of large RNA molecules

Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promising tool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles. But the difficulties of producing long-lasting, therapeutic RNA that remains stable and non-toxic while entering targeted cells have posed challenges for their progress.

22 Apr 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Clontech releases iDimerize inducible dimerization systems

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT™ technology developed by ARIAD Pharmaceuticals, Inc., the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers.

20 Apr 2011

Study demonstrates clinical effectiveness of Systagenix ADAPTIC TOUCH as a primary wound contact layer

Systagenix announced on 20 April 2011 that a recent product evaluation published in the journal Wounds UK, Vol 7, No 1, demonstrates the clinical effectiveness of ADAPTIC TOUCH® as a primary wound contact layer that addresses the needs of both patients and healthcare professionals.

20 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

Periodontal ligament stem cells most efficacious among dental tissue-derived stem cells

Periodontal ligament stem cells (PDLSCs) have been found to be the most efficacious of three kinds of clinically tested dental tissue-derived stem cells, reports a study published in the current issue of Cell Transplantation (20:2), freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.

12 Apr 2011

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011